¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2022³â ´ëÇÑÁø´Ü°Ë»çÀÇÇÐȸ ÃæûÁöȸ 12¿ù Áý´ãȸ : 2022-12-20

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2022³â ´ëÇÑÁø´Ü°Ë»çÀÇÇÐȸ ÃæûÁöȸ 12¿ù Áý´ãȸ : 2022-12-20
±³À°ÀÏÀÚ : 2022-12-20
±³À°Àå¼Ò : ¹ÙÀÌ¿À´Ï¾Æ ±Û·Î¹ú¼¾ÅÍ ´ëÀü±¤¿ª½Ã À¯¼º±¸ °üÆòµ¿ 686  
±³À°ÁÖÁ¦ : 2022³â ´ëÇÑÁø´Ü°Ë»çÀÇÇÐȸ ÃæûÁöȸ 12¿ù Áý´ãȸ
ÁÖÃÖ±â°ü : ´ëÇÑÁø´Ü°Ë»çÀÇÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ÃæûÁöȸ  
´ã´çÀÚ : ÀÌÀ¯Áø
¿¬¶ôó : 070-4436-3304  
À̸ÞÀÏ : kscp2@kams.or.kr      
±³À°Á¾·ù : Áø´Ü°Ë»çÀÇÇаú      
Âü¼®¿¹»óÀοø : 30¸í
Èñ¸ÁÆòÁ¡ : 2Á¡  
Áö¿ª : ´ëÀü±¤¿ª½Ã
±³À°½Ã°£ : 2 ½Ã°£ 30ºÐ  
¼¼ºÎ¼ö°­·á : 0¿ø      
ºñ°í       

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 12-20 PART1 16:10~16:25 Clinical Laboratory Innovations During COVID-19 Pandemic  Marrisa Orillaza(Department of Laboratory Medicine ACE Group of Hospitals) 
±³À°½Ã°£ 12-20 PART1 16:25~16:40 Latest Situation of COVID-19 in Hong Kong  Daniel Tam(CryolifeCompany Ltd) 
±³À°½Ã°£ 12-20 PART1 16:40~16:55 Pandemic Preparedness and Response: A Singapore Experience  Eddie Ang(Singapore Association for Medical Laboratory Sciences) 
±³À°½Ã°£ 12-20 PART1 16:55~17:10 Laboratory Response for COVID-19 in Korea  È«±âÈ£(¿¬¼¼ÀÇ´ë ¼¼ºê¶õ½ºº´¿ø) 
±³À°½Ã°£ 12-20 PART1 17:10~17:25 The Impact of COVID on the Blood Safety Program  Dorothy K. Byabazaire(Uganda Blood Transfusion Service Kampala) 
±³À°½Ã°£ 12-20 PART1 17:25~17:40 Analyse the Factors Affecting the Decision of EQA Sample Selection  Thai My Tran(Center for Standardization and Quality control in medical laboratory of HCMC, University of Economics Ho Chi Minh City) 
±³À°½Ã°£ 12-20 PART2 18:15~18:30 Challenges of Blood Donor Screening in Korea  ±èÇö¿Á(¿¬¼¼ÀÇ´ë ¼¼ºê¶õ½ºº´¿ø) 
±³À°½Ã°£ 12-20 PART2 18:30~18:45 HIV, HBV, HCV Quantitative Measurement and Clinical Application  ¹ÚÈñ¼ö(ÃæºÏ´ëÇб³º´¿ø) 
±³À°½Ã°£ 12-20 PART2 18:45~19:00 Advances in Antiviral Therapy and Viral Load Monitoring  ÀÌÇѾÆ(ÀÌ´ë¸ñµ¿º´¿ø) 
±³À°½Ã°£ 12-20 PART2 19:00~19:15 Laboratory Operations for Viral Load Testing and Surveillance  ¾çÁ¤¼®(°í´ë±¸·Îº´¿ø) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2022³â ´ëÇÑÁø´Ü°Ë»çÀÇÇÐȸ ÃæûÁöȸ 12¿ù Áý´ãȸ : 2022-12-20""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û (¿Â¶óÀÎ) ´ëÇÑÁ¤Çü¿Ü°ú ºÎ»ê․¿ï»ê․°æ³²Áöȸ Á¦351Â÷ ¿Â¶óÀÎ ¿ù·ÊÇмúȸ : 2022-12-20
´ÙÀ½±Û (¿Â¶óÀÎ)2022 ´ëÇÑÀÀ±ÞÀÇ·áÁöµµÀÇ»çÇùÀÇȸ ÁöµµÀÇ»ç µ¿°è ¿¬¼ö°­Á : 2022-12-20
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20694 ´ëÀü Á¦8ȸ ³»ºÐºñ ÃÊÀ½ÆÄ ¹× ±â´É°Ë»ç ¿¬¼ö°­Á : 2024-06-29 0 36 2024-05-11
20693 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 4Â÷ : 2024-06-29 0 34 2024-05-11
20692 ¼­¿ï Á¦24ȸ ´ëÇÑÀ¯Àü¼º´ë»çÁúȯÇÐȸ Á¤±âÇмú´ëȸ : 2024-06-28 0 35 2024-05-11
20691 °æ±â Á¤½Å°Ç°­ÀÇÇаú ÀÓ»ó¿¡¼­ À¯¿ëÇÑ Ä¡·á¹ý : 2024-06-26 0 42 2024-05-11
20690 ¼­¿ï (¿Â¶óÀÎ)2024 ÇѾç´ëÇб³º´¿ø È£Èí±â¾Ë·¹¸£±â ¿¬¼ö°­Á : 2024-06-22 0 36 2024-05-11
20689 ºÎ»ê °í½Å´ëÇб³º¹À½º´¿ø Á¦20ȸ °©»ó¼±¿¬¼öȸ : 2024-06-22 0 27 2024-05-11
20688 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 3Â÷ : 2024-06-22 0 8 2024-05-11
20687 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (2ÀÏÂ÷) : 2024-06-22 0 11 2024-05-11
20686 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 2 : 2024-06-21 0 25 2024-05-11
20685 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (1ÀÏÂ÷) : 2024-06-21 0 13 2024-05-11
20684 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 1 : 2024-06-20 0 11 2024-05-11
20683 ¼­¿ï ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ (¿Â¶óÀÎ) ¼­¿ï°æÀÎÁöȸ 277Â÷ ¿ù·ÊÁý´ãȸ : 2024-06-18 0 29 2024-05-11
20682 ¼­¿ï 2024 °­µ¿±¸ÀÇ»çȸ Á¦3Â÷ ¿¬¼ö±³À°(¿°Áõ¼º ÀåÁúȯ,ºñ¸¸ ¾à¹° Ä¡·á ) : 2024-06-17 0 16 2024-05-11
20681 ¼­¿ï ´ëÇÑ´ç´¢º´ÇÐȸ Á¦29Â÷ ´ç´¢º´ ¿¬¼ö°­Á : 2024-06-16 0 25 2024-05-11
20680 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 2Â÷ : 2024-06-15 0 19 2024-05-11
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷